Lateral flow immunoassay for proteins

Nan, Xuanxu; Li, Yang; Cui, Yue

doi:10.1016/j.cca.2023.117337

Cited by 10 publications

(2 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When developing LFIAs, the primary emphasis has largely been placed on identifying the most appropriate detection method, or selecting the optimal antibody or antigen. However, it is crucial to give due consideration to every component of the test, encompassing fundamental elements like the adhesive strip, cover tape, and backing card, to ensure the creation of a reliable and superior-quality product [ 92 , 93 , 94 ]. The overlapping membranes that are firmly linked to a backing card comprise the conventional LFIA test strip, as seen in Figure 6 .…”

Section: Lateral Flow Immunoassay (Lfia)mentioning

confidence: 99%

Recent Advances in Quantum Dot-Based Lateral Flow Immunoassays for the Rapid, Point-of-Care Diagnosis of COVID-19

et al. 2023

View full text Add to dashboard Cite

The COVID-19 pandemic has spurred demand for efficient and rapid diagnostic tools that can be deployed at point of care to quickly identify infected individuals. Existing detection methods are time consuming and they lack sensitivity. Point-of-care testing (POCT) has emerged as a promising alternative due to its user-friendliness, rapidity, and high specificity and sensitivity. Such tests can be conveniently conducted at the patient’s bedside. Immunodiagnostic methods that offer the rapid identification of positive cases are urgently required. Quantum dots (QDs), known for their multimodal properties, have shown potential in terms of combating or inhibiting the COVID-19 virus. When coupled with specific antibodies, QDs enable the highly sensitive detection of viral antigens in patient samples. Conventional lateral flow immunoassays (LFAs) have been widely used for diagnostic testing due to their simplicity, low cost, and portability. However, they often lack the sensitivity required to accurately detect low viral loads. Quantum dot (QD)-based lateral flow immunoassays have emerged as a promising alternative, offering significant advancements in sensitivity and specificity. Moreover, the lateral flow immunoassay (LFIA) method, which fulfils POCT standards, has gained popularity in diagnosing COVID-19. This review focuses on recent advancements in QD-based LFIA for rapid POCT COVID-19 diagnosis. Strategies to enhance sensitivity using QDs are explored, and the underlying principles of LFIA are elucidated. The benefits of using the QD-based LFIA as a POCT method are highlighted, and its published performance in COVID-19 diagnostics is examined. Overall, the integration of quantum dots with LFIA holds immense promise in terms of revolutionizing COVID-19 detection, treatment, and prevention, offering a convenient and effective approach to combat the pandemic.

show abstract

Section: Lateral Flow Immunoassay (Lfia)mentioning

confidence: 99%

Recent Advances in Quantum Dot-Based Lateral Flow Immunoassays for the Rapid, Point-of-Care Diagnosis of COVID-19

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Currently, the use of colloidal gold lateral flow immunoassay (LFIA) 7 has rapidly increased. LFIA relies on antigen−antibody interactions 8 and has been widely used in food safety, biomedical fields, and for detecting drugs, 9 bacteria, 10 proteins, 11 and viruses 12 due to its simplicity and high efficiency. However, this method has limitations, in terms of assay accuracy and sensitivity.…”

Section: ■ Introductionmentioning

confidence: 99%

Comprehensive SERS–LFIA Platform for Ultrasensitive Detection and Automated Discrimination of Chloramphenicol Residues in Aquatic Products

Zhao,

Lin,

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

With the increasing misuse of antibiotic drugs, the convenient and ultrasensitive detection of chloramphenicol (CAP) is essential for ensuring food safety and human health. In this study, a comprehensive platform was developed integrating detection and discrimination capabilities by combining surfaceenhanced Raman scattering (SERS) with lateral flow immunoassay (LFIA) technology, along with a support vector machine (SVM) model for data analysis, to detect CAP residues in aquatic products. The CAP-specific antibody-modified gold nanostars (Au NSs) were synthesized as SERS−LFIA nanoprobes, achieving an ultralow limit of detection (LOD) of 10 pg/mL and a theoretical LOD of 1.6 pg/mL for simulated aquatic samples. This sensitivity surpasses that of the currently available commercial strips and demonstrates high specificity. Additionally, the automated discrimination model exhibited high sensitivity (95.83%) and specificity (96.43%) as well as an accuracy of 96% on the test set, marking an 8% improvement over traditional Raman intensity discrimination methods. This developed platform is a simple, fast, and automated technique that eliminates the need for sample pretreatment, offering a promising approach for the trace detection of CAP in aquatic products.

show abstract

Afterglow Nanoprobes for In-vitro Background-free Biomarker Analysis

Zheng,

Wang,

et al. 2024

Chem. Res. Chin. Univ.

View full text Add to dashboard Cite

Lateral flow immunoassay for proteins

Cited by 10 publications

References 164 publications

Recent Advances in Quantum Dot-Based Lateral Flow Immunoassays for the Rapid, Point-of-Care Diagnosis of COVID-19

Recent Advances in Quantum Dot-Based Lateral Flow Immunoassays for the Rapid, Point-of-Care Diagnosis of COVID-19

Comprehensive SERS–LFIA Platform for Ultrasensitive Detection and Automated Discrimination of Chloramphenicol Residues in Aquatic Products

Afterglow Nanoprobes for In-vitro Background-free Biomarker Analysis

Contact Info

Product

Resources

About